BridgeBio Oncology Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is BBOT moving today?
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BBOT.
BBOT insider activity
BridgeBio Oncology Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$44K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | 2026-07-01 | Elmelech Idan | Insider | sell | $7.80 | 343 | 14,495 | $3K | SEC Form 4 |
| 2026-07-06 | 2026-07-01 | Ben Yong | Insider | sell | $7.80 | 1,047 | 44,576 | $8K | SEC Form 4 |
| 2026-07-06 | 2026-07-01 | Beltran Pedro | Insider | sell | $7.80 | 1,047 | 44,576 | $8K | SEC Form 4 |
| 2026-07-06 | 2026-07-01 | Cobo Marc | Insider | sell | $7.80 | 125 | 5,306 | $975 | SEC Form 4 |
| 2026-05-05 | 2026-04-01 | Ben Yong | Insider | sell | $9.03 | 1,047 | 45,623 | $9K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 2 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moBBOT contract awards, year to date.
Public federal awards linked to this ticker.
BBOT lobbying filings, year to date.
Registered lobbying filings matched to BridgeBio Oncology Therapeutics, Inc. Common Stock.